{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-028647","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.662800+00:00","generated_at":"2026-06-05T00:41:56.072534+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Janux reports $344M year-end cash; Q4 net loss $11.8M; positive Phase 1 JANX007/JANX008 data","bullets":["Year-end cash & investments $344M; net loss $58.3M for FY 2023 vs $63.1M in 2022.","Raised ~$320.2M net in March 2024 underwritten offering to fund clinical pipeline.","Phase 1 JANX007 in mCRPC: 83% PSA50 at first step dose ≥0.2mg; no CRS > Grade 2.","Phase 1 JANX008: NSCLC subject achieved RECIST PR with 100% target lesion reduction, no CRS.","Co-founder Dr. Tommy DiRaimondo promoted to CSO; JANX007 update expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-028647","json":"https://secwatch.observer/filing/0000950170-24-028647.json","markdown":"https://secwatch.observer/filing/0000950170-24-028647.md","text":"https://secwatch.observer/filing/0000950170-24-028647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024028647/0000950170-24-028647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024028647/janx-20240308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:41:56.072534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd1f8bff824dd5634478a14259f0b1cc6a948bff","claim":"Janux Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $11.8 million for the quarter and $58.3 million for the year ended December 31, 2023.","evidence_excerpt":"Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024028647/0000950170-24-028647-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $11.8 million for the quarter and $58.3 million for the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}